Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Protocol: Sacituzumab Govitecan + Pembrolizumab for Triple-Negative Metastatic Breast Cancer
ASCENT-04 phase 3 trial showed that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival compared to chemotherapy plus pembrolizumab in patient
New Protocol: Lenvatinib with Bevacizumab for Gynecological Clear Cell Carcinoma
In this phase 2 trial of pembrolizumab plus lenvatinib in patients with recurrent gynaecological clear cell carcinoma, the combination of lenvatinib and pembrolizumab showed a 40%
New Protocol: Letrozole and Palbociclib with Trastuzumab and Pertuzumab for Neoadjuvant Triple-Positive Breast Cancer
The TOUCH trial showed that palbociclib and letrozole combined with dual anti-HER2 therapy achieved similar pCR rates to paclitaxel in HR-positive/HER2-positive early breast cancer
New Reference: Palbociclib Addition to Maintenance Therapy in Triple-Positive Breast Cancer
The addition of palbociclib to maintenance anti-HER2 and endocrine therapies significantly improved progression-free survival in patients with hormone-receptor-positive, HER2-posit
New Reference: Olaparib for PALB2 or BRCA1/2 Mutated Breast Cancer
The phase II TBCRC 048 study found olaparib to be effective in metastatic breast cancer patients with germline PALB2 or somatic BRCA1/2 mutations. The overall response rate was sig
New Protocol: Ultra-Low Dose Nivolumab for Advanced Solid Tumors
Ultra-low-dose nivolumab significantly improved overall survival compared to chemotherapy in patients with relapsed refractory solid tumors while reducing severe toxicities. The re
New Reference: Nivolumab for Advanced Gastric/Esophageal AdenoCa
Nivolumab combined with chemotherapy continues to show superior overall survival and progression-free survival compared to chemotherapy alone at 5 years in advanced gastroesophagea
New Reference: Camrelizumab with Chemotherapy for Advanced Nasopharyngeal Carcinoma
The addition of camrelizumab to chemotherapy provided significant improvement in overall survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The trial demon
New Drug: Anbenitamab for HER2-Positive Gastric Cancer
The study illustrates that anbenitamab plus chemotherapy significantly improves progression-free survival and overall survival in patients with HER2-positive gastric cancer who hav
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.